secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2023-11-17T23:59:59+00:00
Accession:  0001558370-23-019194
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma signs 5-year manufacturing contract with Halo for two ADHD products
--------------------------------------------------------------------------------

- Entered Commercial Manufacturing Services Agreement with Halo Pharmaceutical for Adzenys XR ODT and Cotempla XR ODT.
- Initial term from Nov 13, 2023 to Nov 13, 2028; auto-renews for successive 3-year terms.
- Company must purchase 100% of its requirements for covered products from Halo, except for own manufacturing.
- Company supplies active ingredients; Halo handles manufacturing, QC, packaging, and validation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000155837023019194/0001558370-23-019194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000155837023019194/aytu-20231113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-019194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer